Coya Therapeutics, Inc. (COYA) Financial Analysis & Valuation | Quarter Chart
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, ... more
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal prod... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $117.05M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Arun Swaminathan |
| IPO Date | 2022-12-29 | CAGR | — |
| Employees | 8 | Website | www.coyatherapeutics.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
COYA chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $-43.04B | P/E | -4.8 | Forward P/E | -2.63 | PEG | -0.42 |
| P/S | 0.49 | P/B | — | P/CF | -0.01 | P/FCF | -0.01 |
| Sales | $251.52M | Sales 1Y | 59297.62% | Sales 3Y | inf% | Sales 5Y | — |
| EPS | $-1.04 | EPS 1Y | -13.71% | EPS 3Y | -24.11% | EPS 5Y | — |
| Sales QoQ | 96952.72% | EPS QoQ | -12.5% | Sales QoQ Avg | 24737.15% | EPS QoQ Avg | 19.82% |
| Gross Margin | 100% | Operating Margin | -2807.95% | Profit Margin | -2645.23% | ROCE | -16.13% |
| ROA | -14% | ROE | -61% | Altman Z Score | -1.61 | Piotroski Score | 3 |
| Current Ratio | 13.4 | Quick Ratio | 13.4 | Cash Ratio | 12.29 | Op. CF Ratio | -3.89 |
| Debt/Equity | — | Debt/Assets | — | Lt Debt/Equity | — | Lt Debt/Cap. | — |
| Intrst Cov. | — | Inventory Turnover | — | Asset Turnover | 0.01 | Receivables Turnover | — |
| Enterprise Value | $-43.04B | P/E Ratio | -4.8 |
| Forward P/E | -2.63 | PEG Ratio | -0.42 |
| P/S Ratio | 0.49 | P/B Ratio | — |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-1.04 | EPS Growth 1Y | -13.71% |
| EPS Growth 3Y | -24.11% | EPS Growth 5Y | — |
| Revenue Growth 1Y | 59297.62% | Gross Margin | 100% |
| Operating Margin | -2807.95% | Profit Margin | -2645.23% |
| ROE | -61% | ROA | -14% |
| ROCE | -16.13% | Current Ratio | 13.4 |
| Quick Ratio | 13.4 | Cash Ratio | 12.29 |
| Debt/Equity | — | Interest Coverage | — |
| Altman Z Score | -1.61 | Piotroski Score | 3 |
Coya Therapeutics, Inc. (COYA) valuation & financials
Coya Therapeutics, Inc. (COYA) has a market capitalization of $117.05M and trades at a price-to-earnings ratio of -4.8. It operates in the Healthcare sector (Biotechnology).
Coya Therapeutics, Inc.'s revenue grew +59297.6% over the last year.
Coya Therapeutics, Inc.'s next earnings report is scheduled for November 11, 2026 before market open (provider scheduled date); analysts estimate EPS of $-0.35. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)